

Nazorg bij gemetastaseerd prostaatacarcinoom

Key question

Bij patiënten die behandeld zijn ivm gemetastaseerd prostaatacarcinoom, leidt deze behandeling tot somatische en/of psychische problemen in het 1e jaar na behandeling?

P: Patiënten die behandeld zijn ivm gemetastaseerd prostaatacarcinoom

I: Behandeling van gemetastaseerd prostaatacarcinoom (hormonale therapie)

C: Geen behandeling

O: Somatische en/of psychische problemen in het 1e jaar na behandeling (opvliegers, gewichtstoename, depressie, gewrichtsklachten, osteoporose, pijnlijke gynaecomastie)

Search strategy

Searches were run on September 2nd 2012 (an additional search in Medline was run on September 14th 2012).

OVID Medline, Embase and the CDSR were searched. Detailed search strings are given below.

The search limits were: 2007-2012; English and Dutch; only systematic reviews.

Search results

The Medline and Pre-Medline search yielded 638 and 5 hits respectively, while the Embase search yielded 121 hits. The search in the CDSR yielded 17 Cochrane reviews.

The additional Medline search yielded 18 extra hits.

Excluded studies

After merging the search files into 1 file and removal of the duplicates, 693 hits were screened on title and abstract. Of these, 672 were excluded. The most important reasons for exclusion were:

- Wrong cancer type
- Adverse events of wrong intervention
- Wrong study design (e.g. case report, narrative review, etc.)
- Treatment of adverse event

Of the remaining 21 studies, the full-text was retrieved. Based on the full-text, an additional 18 studies were excluded. **Fout! Verwijzingsbron niet gevonden.**4 provides an overview of excluded studies, with the reasons for exclusion.

Table 14. Overview of excluded studies based on full-text evaluation

First author	Reference	Title	Reason(s) for exclusion
Abrahamsson P-A	Eur Urol 2010 57(1):49-59	Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature	Geen kwaliteitsbeoordeling, enkel gezocht in Medline
Anguiano L	Cancer Nurs. 2012 35(4):E14-E26	A literature review of suicide in cancer patients	Geen afzonderlijke resultaten voor hormonale therapie en gemetastaseerde ziekte
Eastham JA	J Urol 2007 177(1):17-24	Bone health in men receiving androgen deprivation therapy for prostate cancer	Narratieve review
Freedland SJ	Prostate Cancer & Prostatic Diseases 2009 12(4):333-8	Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer	Narratieve review
Fritzsche K	Z. Psychosom. Med.	Psychosocial distress and treatment	Geen afzonderlijke resultaten

First author	Reference	Title	Reason(s) for exclusion
	Psychother. 2008 54(4):329-353	approaches: A systematic review	voor hormonale therapie en gemetastaseerde ziekte
Hakimian P	BJU Int 2008 102(11):1509-14	Metabolic and cardiovascular effects of androgen deprivation therapy	Geen kwaliteitsbeoordeling, enkel gezocht in Medline
Isbarn H	Eur Urol 2009 55(1):62-75	Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks	Geen kwaliteitsbeoordeling, enkel gezocht in Medline
Kintzel PE	Pharmacotherapy 2008 28(12):1511-22	Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer	Geen kwaliteitsbeoordeling, enkel gezocht in Medline
Loblaw DA	J Clin Oncol 2007 25(12):1596-605	Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline	Geen kwaliteitsbeoordeling
Pfitzenmaier J	Dtsch 2009 106(14):242-7	Hormonal therapy in the elderly prostate cancer patient	Geen kwaliteitsbeoordeling, geen details over search
Ribeiro AF	Arq Bras Cardiol 2010 95(3):412-5	Cardiovascular risks of androgen deprivation therapy	Geen kwaliteitsbeoordeling, enkel gezocht in Medline
Sasse AD	BMC Cancer 2012 12(54):	Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review	Geen (gekwantificeerde) gegevens over adverse events
Saylor PJ	J Urol 2009 181(5):1998-2006; discussion 2007-8	Metabolic complications of androgen deprivation therapy for prostate cancer	Geen kwaliteitsbeoordeling, enkel gezocht in Medline
Schwandt A	Curr Opin Urol 2009 19(3):322-6	Complications of androgen deprivation therapy in prostate cancer	Narratieve review
Serpa Neto A	BMC Urol. 2010 10	A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma	Geen kwaliteitsbeoordeling, maar wel relevant
Sprenkle PC	Curr Opin Urol 2007 17(6):424-30	Pathologic effects of testosterone deprivation	Narratieve review
Taylor LG	Cancer 2009 115(11):2388-99	Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer	Geen kwaliteitsbeoordeling, maar wel relevant
Vigano A	Lancet Oncol. 2010 11(7):679-684	Male hypogonadism associated with advanced cancer: A systematic review	Irrelevante outcomes

Included studies

Three reviews were included for quality appraisal and data extraction:

- De Conti PD et al. Cochrane Database Syst. Rev.(4). Intermittent versus continuous androgen suppression for prostatic cancer.
- Haseen F et al. J Cancer Surviv. 2010 Jun;4(2):128-39. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis.
- Zhu J et al. J BUON. 2012 Apr-Jun;17(2):350-6. Intermittent androgen blockade or continuous androgen blockade in advanced prostate cancer: a meta-analysis of efficacy, quality of life and side effects.